How does the neurologist, geriatrician, or movement disorder specialist confirm the diagnosis of Parkinson’s Disease as a prelude or trigger to beginning pharmacologic therapy? What are the pathognomonic features of this disease state?
Published: July 27, 2022
How does the neurologist, geriatrician, or movement disorder specialist confirm the diagnosis of Parkinson’s Disease as a prelude or trigger to beginning pharmacologic therapy? What are the pathognomonic features of this disease state?
How does the neurologist, geriatrician, or movement disorder specialist confirm the diagnosis of Parkinson’s Disease as a prelude or trigger to beginning pharmacologic therapy? What are the pathognomonic features of this disease state?
Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.
